The imaging artificial intelligence developer Quibim has raised $50 million in venture capital funding, to support its work ...

Just a few years ago, children with Type 1 diabetes reported to the school nurse several times a day to get a finger pricked ...

The drug in question, called firicabtagene autoleucel or firi-cel, is an autologous CD22 CAR-T cell therapy that had been ...

Inhibikase Therapeutics is pausing work on its experimental Parkinson’s disease drug risvodetinib and seeking “strategic ...

Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 ...

Sanofi has removed a clutch of programs from its clinical pipeline, scratching out entries for its late-phase BTK inhibitor and phase 1 prospects linked to the multibillion-dollar takeovers of Ablynx, ...

Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the plug on the program after the FDA pointed out the shortcomings of its ...

Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked up from Xencor. | Roche has given two early-phase bispecifics the heave-ho ...

We hoped industry layoffs would relent in 2024. That's not what happened. Overall, biopharma layoffs rose 3% last year compared to 2023, according to an analysis of yearly data. So, here we are ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

Trouble sleeping is common in other neurodegenerative diseases, but past research has only suggested that it occurs in ...

Stryker is selling off its spine implant business—starting with a plan to spin off its U.S. operations before moving on to ...